sparteine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2467 | 90-39-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A quinolizidine alkaloid isolated from several FABACEAE including LUPINUS; SPARTIUM; and CYTISUS. It has been used as an oxytocic and an anti-arrhythmia agent. It has also been of interest as an indicator of CYP2D6 genotype.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | P |
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01BA04 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY ANTIARRHYTHMICS, CLASS I AND III Antiarrhythmics, class Ia |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D010120 | Oxytocics |
| MeSH PA | D012102 | Reproductive Control Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.96 | Basic |
| pKa2 | 8.06 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D01041 | KEGG_DRUG |
| 6160-12-9 | SECONDARY_CAS_RN |
| C0037760 | UMLSCUI |
| CHEBI:28827 | CHEBI |
| CHEMBL412873 | ChEMBL_ID |
| DB06727 | DRUGBANK_ID |
| D013034 | MESH_DESCRIPTOR_UI |
| 644020 | PUBCHEM_CID |
| 1447 | INN_ID |
| 298897D62S | UNII |
| 001311 | NDDF |
| 006191 | NDDF |
| 377002 | SNOMEDCT_US |
| 412311003 | SNOMEDCT_US |
| CHEMBL2303617 | ChEMBL_ID |
Pharmaceutical products:
None